GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (NAS:CRBP) » Definitions » E10

CRBP (Corbus Pharmaceuticals Holdings) E10 : $-22.86 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Corbus Pharmaceuticals Holdings E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Corbus Pharmaceuticals Holdings's adjusted earnings per share data for the three months ended in Sep. 2024 was $-1.150. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-22.86 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-13), Corbus Pharmaceuticals Holdings's current stock price is $15.00. Corbus Pharmaceuticals Holdings's E10 for the quarter that ended in Sep. 2024 was $-22.86. Corbus Pharmaceuticals Holdings's Shiller PE Ratio of today is .


Corbus Pharmaceuticals Holdings E10 Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings E10 Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -22.15

Corbus Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.09 -22.15 -22.62 -22.77 -22.86

Competitive Comparison of Corbus Pharmaceuticals Holdings's E10

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Shiller PE Ratio falls into.



Corbus Pharmaceuticals Holdings E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corbus Pharmaceuticals Holdings's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-1.15/133.0289*133.0289
=-1.150

Current CPI (Sep. 2024) = 133.0289.

Corbus Pharmaceuticals Holdings Quarterly Data

per share eps CPI Adj_EPS
201412 -1.458 99.070 -1.958
201503 -1.800 99.621 -2.404
201506 -3.000 100.684 -3.964
201509 -1.800 100.392 -2.385
201512 -1.800 99.792 -2.400
201603 -2.400 100.470 -3.178
201606 -3.300 101.688 -4.317
201609 -3.600 101.861 -4.702
201612 -5.400 101.863 -7.052
201703 -4.800 102.862 -6.208
201706 -4.500 103.349 -5.792
201709 -4.200 104.136 -5.365
201712 -6.300 104.011 -8.058
201803 -6.300 105.290 -7.960
201806 -6.300 106.317 -7.883
201809 -7.800 106.507 -9.742
201812 -9.000 105.998 -11.295
201903 -12.900 107.251 -16.001
201906 0.900 108.070 1.108
201909 -9.600 108.329 -11.789
201912 -12.300 108.420 -15.092
202003 -12.900 108.902 -15.758
202006 -15.600 108.767 -19.080
202009 -12.900 109.815 -15.627
202012 -3.000 109.897 -3.631
202103 -4.200 111.754 -5.000
202106 -4.500 114.631 -5.222
202109 -0.600 115.734 -0.690
202112 -2.400 117.630 -2.714
202203 -2.260 121.301 -2.479
202206 -3.180 125.017 -3.384
202209 -2.110 125.227 -2.241
202212 -2.610 125.222 -2.773
202303 -4.240 127.348 -4.429
202306 -2.050 128.729 -2.118
202309 -2.270 129.860 -2.325
202312 -1.790 129.419 -1.840
202403 -0.830 131.776 -0.838
202406 -0.900 132.554 -0.903
202409 -1.150 133.029 -1.150

Add all the adjusted EPS together and divide 10 will get our e10.


Corbus Pharmaceuticals Holdings  (NAS:CRBP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Corbus Pharmaceuticals Holdings E10 Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Executives
Yuval Cohen director, officer: Chief Executive Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Sean F. Moran officer: Chief Financial Officer 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046
Yong Ben director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Anne Altmeyer director 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Craig Stuart Millian officer: Chief Commercial Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachael Louise Brake officer: Chief Scientific Officer 21 MANCHESTER PLACE, NATICK MA 01760
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Peter Salzmann director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Barbara White officer: Chief Medical Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Paul Discordia officer: Chief Operating Officer C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
David P Hochman director 15 WESTON HILL RD., RIVERSIDE CT 06878
John Kenneth Jenkins director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Avery W Catlin director 241 CENTRAL STREET, HINGHAM MA 02043